Orgalutran

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ganirelix

Available from:

N.V. Organon

ATC code:

H01CC01

INN (International Name):

ganirelix

Therapeutic group:

Hipofize in hipotalamični hormoni in analogi

Therapeutic area:

Reproductive Techniques, Assisted; Ovulation Induction; Infertility, Female

Therapeutic indications:

Preprečevanje prezgodnje skokovitega luteinising hormona pri ženskah v postopku pod nadzorom Hiperstimulacije jajčnikov za reprodukciji tehnike. V kliničnih študijah, Orgalutran je bila uporabljena s rekombinantne človeške folikle stimulirajočega hormona ali corifollitropin alfa, trajno folikle stimulans.

Product summary:

Revision: 24

Authorization status:

Pooblaščeni

Authorization date:

2000-05-16

Patient Information leaflet

                                15
Shranjujte v originalni ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
N.V. Organon
Kloosterstraat 6
5349 AB Oss
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/00/130/001 1 napolnjena injekcijska brizga
EU/1/00/130/002 5 napolnjenih injekcijskih brizg
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
16
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH VOJNINAH
BESEDILO NA NAPOLNJENIH INJEKCIJSKIH BRIZGAH ZDRAVILA ORGALUTRAN
0,25 MG/0,5 ML
1.
IME ZDRAVILA IN POT(I) UPORABE
Orgalutran 0,25 mg/0,5 ml raztopina za injiciranje
ganireliks
subkutana uporaba
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
6.
DRUGI PODATKI
Organon
17
B. NAVODILO ZA UPORABO
18
NAVODILO ZA UPORABO
ORGALUTRAN 0,25 MG/0,5 ML RAZTOPINA ZA INJICIRANJE
ganireliks
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom
ali medicinsko sestro.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom,
farmacevtom ali medicinsko
sestro. Posvetujte se tudi, če opazite katere koli neželene učinke,
ki niso navedeni v tem
navodilu. Glejte poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo Orgalutran in za kaj ga up
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Orgalutran 0,25 mg/0,5 ml raztopina za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena napolnjena injekcijska brizga vsebuje 0,25 mg ganireliksa v 0,5 ml
vodne raztopine. Učinkovina
ganireliks (INN) je sintetični dekapeptid z močnim antagonističnim
delovanjem za naravni
gonadotropin sproščujoči hormon (GnRH). Aminokisline na mestih 1,
2, 3, 6, 8 in 10 naravnega
dekapeptida GnRH so zamenjane tako, da nastane

N-Ac-D-Nal(2)
1
, D-pCIPhe
2
, D-Pal(3)
3
, D-hArg
(Et2)
6
, L-hArg(Et2)
8
, D-Ala
10

-GnRH, z molekulsko maso 1570,4.
Pomožna snov z znanim učinkom:
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na injekcijo, kar
v bistvu pomeni ‘brez natrija’.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
raztopina za injiciranje
bistra in brezbarvna vodna raztopina
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Orgalutran je indicirano za preprečevanje prezgodnjih vrhov
sproščanja luteinizirajočega
hormona (LH) pri ženskah, ki se zdravijo z nadzorovano
hiperstimulacijo jajčnikov (COH - controlled
ovarian hyperstimulation) pri postopkih oploditve z biomedicinsko
pomočjo (ART - assisted
reproduction techniques).
V kliničnih študijah so zdravilo Orgalutran uporabljali skupaj z
rekombinantnim folikle stimulirajočim
hormonom (FSH) ali korifolitropinom alfa, dolgo delujočim
stimulatorjem foliklov.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravilo Orgalutran sme predpisati le specialist, ki je izkušen v
zdravljenju neplodnosti.
Odmerjanje
Orgalutran se uporablja za preprečevanje prezgodnjih vrhov
sproščanja LH pri ženskah, ki se zdravijo
z nadzorovano hiperstimulacijo jajčnikov (COH). Nadzorovana
hiperstimulacija jajčnikov z FSH ali
korifolitropinom alfa se lahko začne na 2. ali 3. dan menstruacije.
Zdravilo Orgalutran (0,25 mg) je
treba injicirati subkutano enkrat na dan, z začetkom na 5. ali 6. dan
dajanja FSH ali na 5. ali 6. dan po
dajanju korifolitropina alfa. Začetek daja
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-04-2023
Public Assessment Report Public Assessment Report Bulgarian 21-07-2013
Patient Information leaflet Patient Information leaflet Spanish 04-04-2023
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 04-04-2023
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 04-04-2023
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 04-04-2023
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 04-04-2023
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 04-04-2023
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet English 04-04-2023
Public Assessment Report Public Assessment Report English 21-07-2013
Patient Information leaflet Patient Information leaflet French 04-04-2023
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 04-04-2023
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 04-04-2023
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-04-2023
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-04-2023
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Maltese 04-04-2023
Public Assessment Report Public Assessment Report Maltese 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 04-04-2023
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 04-04-2023
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 04-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-04-2023
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 04-04-2023
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 04-04-2023
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 04-04-2023
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 04-04-2023
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 04-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-04-2023
Patient Information leaflet Patient Information leaflet Croatian 04-04-2023

Search alerts related to this product

View documents history